Levomed

Levodopa/Carbidopa, the active ingredient in Levomed, is a Levodopa/Carbidopa combination presented as an oral dosage form for oral use. It is used to treat Parkinson's disease and Parkinsonian syndromes in adult patients, helping to improve motor function and reduce disease‑related symptoms.

GNH USA supplies Levomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global distribution, providing customers with consistent product availability and responsive technical support.

Levomed, a Levodopa/Carbidopa combination, is indicated for disorders involving dopaminergic deficiency within the Parkinsonian disease spectrum. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity, and tremor. - Parkinsonian syndrome: alleviates motor dysfunction associated with secondary Parkinsonism. - Drug‑induced Parkinsonism: provides symptomatic relief when other therapies are insufficient. - Early‑stage Parkinson's disease: delays the need for additional dopaminergic agents.

Levodopa/Carbidopa therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dyskinesia

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Hallucinations or psychosis

When prescribing Levomed, clinicians should observe several precautionary measures to ensure safe and effective therapy. - Blood pressure monitoring: check for orthostatic changes especially during treatment initiation. - Dose adjustments: consider renal or hepatic impairment and adjust dose accordingly. - Psychiatric evaluation: monitor for depression, hallucinations, or suicidal thoughts. - Cardiovascular risk: use caution in patients with existing heart disease or arrhythmias. - Drug discontinuation: avoid abrupt cessation to prevent withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Levodopa/Carbidopa interacts with several medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): can cause hypertensive crisis. - Antipsychotics that block dopamine receptors (e.g., haloperidol): diminish therapeutic effect. - Pyridoxine (vitamin B6) in high doses: accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive effect on blood pressure may cause hypotension. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome. - Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours. - Other dopaminergic drugs (e.g., pramipexole): may enhance dyskinesia.